Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium.

Winer KK, Sinaii N, Reynolds J, Peterson D, Dowdy K, Cutler GB Jr

The Journal of clinical endocrinology and metabolism14 Apr 2010Cited by 105 (Europe PMC)

PMID20392870PMCIDPMC2902068DOI10.1210/jc.2009-2464PepBankPUB-20392870

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanRandomized controlled trialEfficacy outcome
In children with hypoparathyroidism, predose serum calcium stayed at or just below normal without significant differences between PTH 1‑34 and comparator.
In plain wordsIn children with hypoparathyroidism, blood calcium did not differ significantly between PTH 1‑34 and calcitriol with calcium and cholecalciferol.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changePredose serum calcium
Study
n = 12
Comparator
Calcitriol plus calcium and cholecalciferol
Analysis
Primary
Outcome group
Electrolyte balance · Endocrine and hormones
Studied dose
Dose not stated · subcutaneous · 3 yearsAs given in this study (human).
Source sentences
Summary
Mean predose serum calcium levels were maintained at, or just below, the normal range, and urine calcium levels remained in the normal range throughout the 3-yr study, with no significant differences between treatment groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Subjects included 12 children aged 5-14 yr with chronic hypoparathyroidism and without severe renal or hepatic insufficiency.Study designThe study was a 3-yr randomized parallel trial comparing twice-daily calcitriol (plus calcium and cholecalciferol in four daily doses) vs. s.c. PTH 1-34 t…
Report a problemFND-2039287001
02HumanRandomized controlled trialEfficacy outcome
In children with hypoparathyroidism, urine calcium remained normal without significant differences between PTH 1‑34 and comparator.
In plain wordsIn children with hypoparathyroidism, urine calcium did not differ significantly between PTH 1‑34 and calcitriol with calcium and cholecalciferol.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeUrine calcium
Study
n = 12
Comparator
Calcitriol plus calcium and cholecalciferol
Analysis
Primary
Outcome group
Electrolyte balance · Kidney and urinary
Studied dose
Dose not stated · subcutaneous · 3 yearsAs given in this study (human).
Source sentences
Summary
Mean predose serum calcium levels were maintained at, or just below, the normal range, and urine calcium levels remained in the normal range throughout the 3-yr study, with no significant differences between treatment groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Subjects included 12 children aged 5-14 yr with chronic hypoparathyroidism and without severe renal or hepatic insufficiency.Study designThe study was a 3-yr randomized parallel trial comparing twice-daily calcitriol (plus calcium and cholecalciferol in four daily doses) vs. s.c. PTH 1-34 t…
Report a problemFND-2039287002
03HumanRandomized controlled trialEfficacy outcome
In children with hypoparathyroidism, corrected creatinine clearance remained normal and did not differ between PTH 1‑34 and comparator.
In plain wordsIn children, kidney filtration stayed normal and did not differ between PTH 1‑34 and calcitriol with calcium and cholecalciferol.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeCorrected creatinine clearance
Study
n = 12
Comparator
Calcitriol plus calcium and cholecalciferol
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · subcutaneous · 3 yearsAs given in this study (human).
Source sentences
Summary
Creatinine clearance, corrected for body surface area, did not differ between groups and remained normal throughout the study.
1 context sentence(design, population, supporting numbers)
Summary · context
Subjects included 12 children aged 5-14 yr with chronic hypoparathyroidism and without severe renal or hepatic insufficiency.Study designThe study was a 3-yr randomized parallel trial comparing twice-daily calcitriol (plus calcium and cholecalciferol in four daily doses) vs. s.c. PTH 1-34 t…
Report a problemFND-2039287003
04HumanRandomized controlled trialEfficacy outcome
In children with hypoparathyroidism, bone turnover markers were mildly elevated during PTH 1‑34 therapy but remained normal during calcitriol therapy.
In plain wordsIn children, bone turnover markers were mildly elevated with PTH 1‑34 but stayed normal with calcitriol therapy.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBone turnover markers
Study
n = 12
Comparator
Calcitriol plus calcium and cholecalciferol
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · subcutaneous · 3 yearsAs given in this study (human).
Source sentences
Summary
Markers of bone turnover were mildly elevated during PTH 1-34 therapy and remained within the normal range during calcitriol therapy.
1 context sentence(design, population, supporting numbers)
Summary · context
Subjects included 12 children aged 5-14 yr with chronic hypoparathyroidism and without severe renal or hepatic insufficiency.Study designThe study was a 3-yr randomized parallel trial comparing twice-daily calcitriol (plus calcium and cholecalciferol in four daily doses) vs. s.c. PTH 1-34 t…
Report a problemFND-2039287004
05HumanRandomized controlled trialEfficacy outcome
In children with hypoparathyroidism, lumbar spine BMD Z-scores stayed normal and did not differ between PTH 1‑34 and comparator.
In plain wordsIn children, spine bone density scores stayed normal and did not differ between PTH 1‑34 and calcitriol with calcium and cholecalciferol.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeLumbar spine BMD Z-score
Study
n = 12
Comparator
Calcitriol plus calcium and cholecalciferol
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · subcutaneous · 3 yearsAs given in this study (human).
Source sentences
Summary
Mean bone mineral density Z-scores at the anterior-posterior lumbar spine, femoral neck, distal radius, and whole body remained within the normal range and did not differ between groups throughout the study.
1 context sentence(design, population, supporting numbers)
Summary · context
Subjects included 12 children aged 5-14 yr with chronic hypoparathyroidism and without severe renal or hepatic insufficiency.Study designThe study was a 3-yr randomized parallel trial comparing twice-daily calcitriol (plus calcium and cholecalciferol in four daily doses) vs. s.c. PTH 1-34 t…
Report a problemFND-2039287005
06HumanRandomized controlled trialEfficacy outcome
In children with hypoparathyroidism, femoral neck BMD Z-scores stayed normal and did not differ between PTH 1‑34 and comparator.
In plain wordsIn children, femoral neck bone density scores did not differ between PTH 1‑34 and calcitriol with calcium and cholecalciferol.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeFemoral neck BMD Z-score
Study
n = 12
Comparator
Calcitriol plus calcium and cholecalciferol
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · subcutaneous · 3 yearsAs given in this study (human).
Source sentences
Summary
Mean bone mineral density Z-scores at the anterior-posterior lumbar spine, femoral neck, distal radius, and whole body remained within the normal range and did not differ between groups throughout the study.
1 context sentence(design, population, supporting numbers)
Summary · context
Subjects included 12 children aged 5-14 yr with chronic hypoparathyroidism and without severe renal or hepatic insufficiency.Study designThe study was a 3-yr randomized parallel trial comparing twice-daily calcitriol (plus calcium and cholecalciferol in four daily doses) vs. s.c. PTH 1-34 t…
Report a problemFND-2039287006
07HumanRandomized controlled trialEfficacy outcome
In children with hypoparathyroidism, distal radius BMD Z-scores stayed normal and did not differ between PTH 1‑34 and comparator.
In plain wordsIn children, wrist bone density scores did not differ between PTH 1‑34 and calcitriol with calcium and cholecalciferol.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeDistal radius BMD Z-score
Study
n = 12
Comparator
Calcitriol plus calcium and cholecalciferol
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · subcutaneous · 3 yearsAs given in this study (human).
Source sentences
Summary
Mean bone mineral density Z-scores at the anterior-posterior lumbar spine, femoral neck, distal radius, and whole body remained within the normal range and did not differ between groups throughout the study.
1 context sentence(design, population, supporting numbers)
Summary · context
Subjects included 12 children aged 5-14 yr with chronic hypoparathyroidism and without severe renal or hepatic insufficiency.Study designThe study was a 3-yr randomized parallel trial comparing twice-daily calcitriol (plus calcium and cholecalciferol in four daily doses) vs. s.c. PTH 1-34 t…
Report a problemFND-2039287007
08HumanRandomized controlled trialEfficacy outcome
In children with hypoparathyroidism, whole body BMD Z-scores stayed normal and did not differ between PTH 1‑34 and comparator.
In plain wordsIn children, whole body bone density scores did not differ between PTH 1‑34 and calcitriol with calcium and cholecalciferol.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeWhole body BMD Z-score
Study
n = 12
Comparator
Calcitriol plus calcium and cholecalciferol
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · subcutaneous · 3 yearsAs given in this study (human).
Source sentences
Summary
Mean bone mineral density Z-scores at the anterior-posterior lumbar spine, femoral neck, distal radius, and whole body remained within the normal range and did not differ between groups throughout the study.
1 context sentence(design, population, supporting numbers)
Summary · context
Subjects included 12 children aged 5-14 yr with chronic hypoparathyroidism and without severe renal or hepatic insufficiency.Study designThe study was a 3-yr randomized parallel trial comparing twice-daily calcitriol (plus calcium and cholecalciferol in four daily doses) vs. s.c. PTH 1-34 t…
Report a problemFND-2039287008
09HumanRandomized controlled trialEfficacy outcome
In children with hypoparathyroidism, height percentiles stayed normal and did not differ between PTH 1‑34 and comparator.
In plain wordsIn children, height percentiles stayed normal and did not differ between PTH 1‑34 and calcitriol with calcium and cholecalciferol.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeHeight percentile
Study
n = 12
Comparator
Calcitriol plus calcium and cholecalciferol
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · subcutaneous · 3 yearsAs given in this study (human).
Source sentences
Summary
Similarly, height and weight percentiles did not differ between treatment groups and remained normal throughout the 3-yr follow-up.
1 context sentence(design, population, supporting numbers)
Summary · context
Subjects included 12 children aged 5-14 yr with chronic hypoparathyroidism and without severe renal or hepatic insufficiency.Study designThe study was a 3-yr randomized parallel trial comparing twice-daily calcitriol (plus calcium and cholecalciferol in four daily doses) vs. s.c. PTH 1-34 t…
Report a problemFND-2039287009
10HumanRandomized controlled trialEfficacy outcome
In children with hypoparathyroidism, weight percentiles stayed normal and did not differ between PTH 1‑34 and comparator.
In plain wordsIn children, weight percentiles stayed normal and did not differ between PTH 1‑34 and calcitriol with calcium and cholecalciferol.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeWeight percentile
Study
n = 12
Comparator
Calcitriol plus calcium and cholecalciferol
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 3 yearsAs given in this study (human).
Source sentences
Summary
Similarly, height and weight percentiles did not differ between treatment groups and remained normal throughout the 3-yr follow-up.
1 context sentence(design, population, supporting numbers)
Summary · context
Subjects included 12 children aged 5-14 yr with chronic hypoparathyroidism and without severe renal or hepatic insufficiency.Study designThe study was a 3-yr randomized parallel trial comparing twice-daily calcitriol (plus calcium and cholecalciferol in four daily doses) vs. s.c. PTH 1-34 t…
Report a problemFND-2039287010

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium.

Summary

Results from this study10

Version history

Subjects

Publication types

MeSH terms